Figure 1 Distribution of WCD use days in WEARIT-II

Slides:

Advertisements

Similar presentations

J Exp Bot. 2017;68(17): doi: /jxb/erx352

Advertisements

Figure 1 Study flow chart.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1. Overview of the workflow of NetworkAnalyst 3.0.

Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 The study area within Vienna Zoo is outlined in red

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 Flow diagram detailing the systematic review process.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 The process of bone defect creation, implant insertion and ridge augmentation. (a) Creation of standardized ... Figure 1 The process of bone defect.

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1. Comparison of weighted estimates of diarrhoea prevalence in children under five by country between PMA Figure 1. Comparison of weighted.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.

Figure 1 The occurrence of maternal cardiovascular events for the different diagnosis groups. AOP, aortic pathology; ... Figure 1 The occurrence of maternal.

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Fig. 1 Mean change from baseline in ANC ± s. e

Point estimates with ... Point estimates with 95% CI. HR: hip replacement; KR: knee replacement. Unless provided in the caption above, the following copyright.

Take home figure The protective role of CNP/NPR-B/NPRC.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

FIGURE 1 Participant flow diagram. Exercise Counseling Clinic (ECC).

Graph 1. The number of homicide cases per year discussing neuro-evidence. Unless provided in the caption above, the following copyright applies to the.

Fig. 1 Flow chart of included patients for analyses

Fig. 1 Flow chart for selection of study subjects

Figure 1. Mean concentration–time profiles of ascending doses of ivermectin in (a) PSAC and (b) SAC. Weight-dependent ... Figure 1. Mean concentration–time.

Figure 1 Nelson-Aalen estimates of the cumulative incidence rates for patients on versus off IST. ON = optic neuritis; ... Figure 1 Nelson-Aalen estimates.

FIGURE 1 Malta: a plate-style food guide

Figure 1. A, Crude incidence rates per 100 person-years of follow-up and 95% confidence intervals for each solid organ ... Figure 1. A, Crude incidence.

Figure 1 Selection algorithm of patients being included in the German Aortic Valve Registry in 2014 and Figure 1 Selection algorithm of patients.

FIGURE 1 Study consort diagram

Fig. 2 Case 2. Levels of serum creatinine and anti-GBM antibodies before and during treatment with cyclophosphamide, ... Fig. 2 Case 2. Levels of serum.

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

FIGURE 1 Food groups consumed (mean, g/d) among US infants and young children by age group and tertile of mean ... FIGURE 1 Food groups consumed (mean,

Figure 1. Schematic diagram of solar energy and coal-fired power generation system. Unless provided in the caption above, the following copyright applies.

Figure 1. Uncertainty reduction, value creation, and appropriation in two case studies. Unless provided in the caption above, the following copyright applies.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent ... Figure 1 Ratio of the geometric mean.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 Patient selection

Figure 1 Patient disposition

Figure 1 Diagram of patient and procedural follow-up for Cohorts A, B, and C. Cohort A: 6-month OCT and 12-month OCT, ... Figure 1 Diagram of patient and.

Figure 1. Trial profile. (A) Part A and (B) part B

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Figure 1 Correlation between en face Oil-Red O staining and aortic root lesion size vs. plasma cholesterol and ... Figure 1 Correlation between en face.

Figure 1. Excess cost of methicillin-resistant Staphylococcus aureus (MRSA) compared with methicillin-susceptible S. ... Figure 1. Excess cost of methicillin-resistant.

Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Patient selection.

Figure 1 Genetic results. No case had more than one diagnostic result

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Figure 1. (A) Baseline contrast-enhanced CT scan of melanoma patient presenting with metastases in the liver and lymph ... Figure 1. (A) Baseline contrast-enhanced.

Figure 1. Prevalence of parasitic infection and anemia among the children. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. GWAS Catalog associations for coronary artery disease plotted across all chromosomes. Associations added ... Figure 1. GWAS Catalog associations.

Source:Zimnisky (2014). Source:Zimnisky (2014).

Figure 1 Mechanisms of mitral regurgitation.

Fig. 1. Examples of plots of NanoPlot and NanoComp

Figure 1 ABCDE of primary prevention.2

Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF clinic, Karachi, Pakistan, March 2016–September ... Figure 1. Hepatitis C screening.

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Figure 1. Enteropathogen prevalence in stool samples collected from 996 children in the Sanitation Hygiene Infant ... Figure 1. Enteropathogen prevalence.

Presentation transcript:

Figure 1 Distribution of WCD use days in WEARIT-II Figure 1 Distribution of WCD use days in WEARIT-II. WCD, wearable cardioverter-defibrillator. Figure 1 Distribution of WCD use days in WEARIT-II. WCD, wearable cardioverter-defibrillator. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Europace, Volume 20, Issue FI2, 14 June 2018, Pages f225–f232, https://doi.org/10.1093/europace/euy091 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 2 Clinical outcomes at the end of WCD use by duration of WCD use. *P < 0.001 for end of use category for ... Figure 2 Clinical outcomes at the end of WCD use by duration of WCD use. *P < 0.001 for end of use category for patients with ≤90 days of total wear vs. >90 days of total wear. EF, ejection fraction; ICD, received implantable cardioverter-defibrillator; WCD, wearable cardioverter-defibrillator. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Europace, Volume 20, Issue FI2, 14 June 2018, Pages f225–f232, https://doi.org/10.1093/europace/euy091 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 3 Clinical outcomes at the end of WCD use by the duration of WCD use and by disease aetiology. *P-value <0.001 ... Figure 3 Clinical outcomes at the end of WCD use by the duration of WCD use and by disease aetiology. *P-value <0.001 for ≤90 vs. >90 total days wear time. <sup>†</sup>P-value <0.001 in the ≤90 days wear time group for EOU by disease aetiology. C/I, congenital or inherited heart disease; EF, ejection fraction; EOU, end of use; ICD, implantable cardioverter-defibrillator; ICM, ischaemic cardiomyopathy; NICM, non-ischaemic cardiomyopathy; WCD, wearable cardioverter-defibrillator. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Europace, Volume 20, Issue FI2, 14 June 2018, Pages f225–f232, https://doi.org/10.1093/europace/euy091 The content of this slide may be subject to copyright: please see the slide notes for details.